Dramatic change in treatment related mortality (TRM) for allogeneic stem cell transplantation (SCT) during recent years. A one centre analysis  by Heilmann, C. et al.
Table. Percentages of pts and Two-Year Rates of NRM and OS in
the Validation Set (n  346) as Scored by the New HCT-Speciﬁc
Comorbidity Index Compared to the Original CCI
HCT-CI pts, %
Two-Year Rate
Original CCI pts, %
Two-Year Rate
NRM, % OS, % NRM, % OS, %
0–1 37 13 72 0 58 17 64
2–3 36 22 58 1 27 33 51
>4 27 40 35 >2 15 31 41
NRM indicates non-relapse mortality; OS, overall survival; CCI,
Charlson comorbidity index; and HCT-CI, hematopoietic cell
transplantation-speciﬁc comorbidity index.
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EFFECTS OF NATURAL KILLER (NK) CELLS ON ALLOGENEIC BONE
MARROW TRANSPLANTATION (BMT) IN FETAL AND NEWBORN MICE
Bhattacharyya, S.; Cowan, M.J. UCSF Children’s Hospital, San Fran-
cisco, CA.
NK cells are capable of receptor-mediated lysis of target cells that
lack self class I MHC molecules. Thus, it is possible that they can be
used effectively in an MHC I mismatched allogeneic BMT to create
myeloablation without developing GVHD. We wanted to deﬁne the
role of the NK cell as a myeloablative agent. C57Bl/6 (B6) adult NK
cells were injected i.p. into 2 day old Balb/c newborns. At various
times post transplant, bone marrow was harvested and in-vitro colony
forming assays were done. We found that allogeneic NK cells de-
stroyed both erythroid and myeloid progenitor cells by 5 days post
injection with some recovery by 19 days. We then injected NK cells
with/without bone marrow from C57Bl/6 (B6) mice into 14 day old
Balb/c fetuses and newborn animals. We found that none of the fetal
recipients survived the in utero transplants even when the number of
NK cells was reduced to 10,000 cells. Histologic studies suggested
severe liver toxicity associated with the fetal injections. In contrast,
7/10 newborn recipients of allogeneic lin BM and NK cells had
multi-lineage engraftment 8 weeks post transplant (Table). The en-
graftment was inhibited by co-administration of anti NK1.1 mAb or
anti-TGF beta antibody suggesting that NK cells play a role in the
engraftment and mediate their effect at least partially through the
secretion of TGF-beta. We used an Artemis deﬁcient TBNK
mouse to study the repopulation of the marrow following transplant
with NK cells. We found signiﬁcant repopulation of T cells (36 	
17% vs 7	 2% control) in blood and thymus with evidence of B cell
reconstitution in bone marrow. NK cells can be used effectively as a
means of enhancing donor cell engraftment and in some circum-
stances inducing multilineage engraftment. This work was supported
by a grant from the NIH NIAID RO1 HL58842 (Table 1).
Engraftment (Percent) in Newborn Balb/c Recipients of B6 NK Cells
and Lin Bone Marrow at 8 Weeks
Groups
Animals
Engrafted
CD3
Cells Granulocytes B Cells Monocytes NK Cells
BM Alone 0/4 0.39  0.11 0.1  0.02 0.1  0.04 0.1  0.02
None
detected
NK  BM 7/10 16.5  6.3 0.5  0.7 2.6  1.0 1.4  1.8 2.1  0.6
NK Alone 3/10
None
detected
None
detected
None
detected
None
detected 5.11  1.4
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LONG TERM INFECTIOUS COMPLICATIONS FOLLOWING REDUCED IN-
TENSITY CONDITIONING (RIC) ALLOGENEIC HLA-IDENTICAL SIBLING
TRANSPLANTATION (ALLO-SCT)
Etienne, A.1; Mohty, M.1; Faucher, C.1; Ferrando, M.1; Benramdane,
R.1; Zandotti, C.2; Collet, L.1; Vey, N.1; Stoppa, A.M.1; Coso, D.1;
Viens, P.1; Gastaut, J.A.1; Blaise, D.1 1. Institut Paoli-Calmettes,
Marseille, France; 2. CHU Timone, Marseille, France.
We analyzed infections occurring beyond 6 months after allo-
SCT, in 81 consecutive pts who received a RIC prior to allo-SCT
from HLA-identical siblings: median age was 49 (18–63) years. 33
(41%), 34 (42%) and 14 (17%) pts had respectively a myeloid,
lymphoid or non-hematological malignancy. 62 pts (77%) had an
advanced disease with high risk clinical features precluding the use
of standard myeloablative allo-SCT. 21 pts (26%) BMT and 60
(74%) PBSCT. RIC consisted of ﬂudarabine and busulfan with
ATG (high dose: 20 (25%); low dose: 50 (62%)) or of low dose
irradiation-based RIC (N11, 13%). With 26 (9–68) months
follow-up, 67 pts (83%) experienced at least one infectious episode
beyond the ﬁrst six months after allo-SCT developing at a median
of 8 (6–34) months. 221 infectious episodes were observed, of
which 123 (56%) required hospitalization and systemic anti-micro-
bial therapy. 94 episodes (43%) could be documented (bacterial,
n28; viral, n56; fungal, n10). Documented infections were:
gram negative bacteria (16%), other bacteria (14%), CMV positive
antigenemia (17%), HSV (25%), VZV (15%), other viruses (3%),
aspergillus (4%), candida species (6%). 81% pts (n54) with an
infection were under systemic immunosuppressive therapy for
chronic GVHD. Moreover, 24 pts (30%) experienced 1 episode
of documented infections (median, 2 episodes; range, 1–12). In a
univariate analysis performed in the pts with documented infec-
tion, age 
50 (P0.06), the use of PBSCs as stem cell source
(P0.03) and a history of DLI (P0.002), exerted a protective
effect against infection occurrence. In a multivariate analysis, DLI
was signiﬁcantly associated with a decreased risk of long term
infections (P0.002; RR0.23; 95% CI, 0.1–0.6), indirectly high-
lighting the protective effect of donor origin immunity after allo-
SCT. In this series of pts surviving at least 6 months after RIC
allo-SCT, the overall long term transplant-related mortality was
14% (n11), of whom 6 deaths were attributed to infections (3
bacterial septicemia, 2 aspergillosis, 1 pneumocystosis), giving a
cumulative incidence of long term-infectious related mortality of
7% (95% CI, 1.4–12.6%). Obviously, prospective efforts to de-
velop optimal antimicrobial preventive strategies after RIC allo-
SCT are still needed. However, the results from this analysis
compare favorably with data from the standard myeloablative allo-
SCT setting.
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DRAMATIC CHANGE IN TREATMENT RELATED MORTALITY (TRM) FOR
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) DURING RECENT
YEARS. A ONE CENTRE ANALYSIS
Heilmann, C.; Laursen, H.B.; Muller, K.; Haastrup, E.; Jacobsen, N.
BMT Unit, Rigshospitalet, University Hospital, Copenhagen, Denmark.
Background: During recent years it has been the impression in
many centres that TRM following allogeneic stem cell transplants
has declined signiﬁcantly. This impression has been strong in our
centre as well. The aim of the present study was to analyze the
magnitude of this presumed reduction in procedure related risks
and to examine possible causes. Method: We analyzed a recent
time period of ten years from Jan. 1994 to Jan. 2003. Non my-
eloablative transplants were excluded from the study. During this
period 224 and 219 standard allotransplants were performed dur-
ing the ﬁrst and the second 5-year time periods respectively. All
transplants were performed at the same centre (Copenhagen, Den-
mark), whose organization has essentially remained the same for
the whole time period. Results: TRM differed signiﬁcantly
(p
0.0001) between the two time periods. The one-year Kaplan-
Meier based TRM declined from 33.5% to 13.9%. On the basis of
univariate analysis no signiﬁcant differences was found between the
compositions of the main diagnosis (AML, ALL, MDS, CML,
non-malignant). Likewise, when the pre-transplant stages of acute
leukaemia and CML were compared between the two periods non
differences were recorded, except that slightly less very high risk
ALL patients were transplanted during the last period. No differ-
ence in age distribution was found. In contrast, a tendency for a
more restrictive donor selection policy could be recorded. Hence,
the composition of donor types (HLA-id Sib vs. other fam. donors
vs. UD; p0.007), donor gender (less female to men; p0.018) and
the use of class I high-resolution donor typing for UD (p0.0001)
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changed between the two time periods. Also, the use of PBSC
instead of BMSC increased (P0.0001). In order to evaluate the
relative importance of these factors a multivariate analysis will be
performed. Conclusion: The pronounced improvement in TRM
during recent years seem to be multi factorial however, an im-
proved donor selection strategy is probably the main cause.
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IMPROVEMENT OF MATCHED SIBLING DONOR ENGRAFTMENT WITH
SIROLIMUS ADDED TO A NON-MYELOABLATIVE CONDITIONING REG-
IMEN
Claxton, D.F.; Ehmann, C.; Shaffer, M.; Rybka, W. Penn State College
of Medicine, Hershey, PA.
Non-myeloablative regimens extend the beneﬁt of allogeneic
hematopoietic transplantation to many otherwise ineligible pa-
tients. Anti-tumor effects are however thought not to occur for
most patients until full donor chimerism is achieved. We have
recently added sirolimus to an established conditioning regimen in
an attempt to optimize engraftment and anti-tumor effects while
minimizing morbid GVHD. We compare results of two sequential
studies conditioning patients with hematological malignancies with
cyclophosphamide (days 7 and 6) and ﬂudarabine (days 7
through 3) prior to matched sibling peripheral blood stem cell
transplantation. All received tacrolimus and methotrexate immu-
noprophylaxis. 9 patients were enrolled in the initial study, and 6/9
also received Campath 1H 20 mg IV on day 7 of the regimen.
The second study has treated 10 patients with sirolimus added to
the immunosuppression and adjusted to 5–15 ng/ml beginning on
day7 (no Campath was given on this study). Tacrolimus has been
tapered off in this protocol between days 30–45, but sirolimus has
continued. Graft versus host disease occurred prior to day 100 in
5/9 patients on protocol 1 and 2/10 patients on protocol 2. In all
cases GVHD was controllable and no patient has died of transplant
related causes. In both protocols all patients showed some degree
of donor engraftment by RFLP or XY FISH analysis by day 30.
Mean fractional peripheral blood donor chimerism values through
day 180 are given in the table below. There is no signiﬁcant
interaction between treatment and time (p-value0.8579), hence
the engraftment curves for the two protocols are parallel. Based on
a repeated measures analysis using general F-statistics, there is a
signiﬁcant treatment effect, with patients on the second protocol
showing an average of 18% higher engraftment (p-value0.0281).
While follow-up is shorter for patients on Protocol 2, 8/10 patients
are beyond 180 days from transplant and the other two have both
achieved 0.98 fractional donor engraftment. We conclude that
our second protocol, using sirolimus with early tapering of tacroli-
mus, appears to yield more rapid and complete donor chimerism
(Table).
Donor Fractional Whole Blood Chimerism
Day 15 Day 30 Day 100 Day 180
Protocol 1 0.51 0.75 0.82 0.81
Protocol 2 with Sirolimus 0.72 0.88 0.99 1.00
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IMATINIB ONLY FOR MOLECULAR RELAPSE IS NOT SUFFICIENT TO
ACHIEVE A DURABLE COMPLETE CHIMERIC STATUS AND MOLECULAR
REMISSION AFTER ALLO HCT IN CML
Soydan, E.; Civriz, S.; Beksac, M.; Koc, H.; Gurman, G.; Ilhan, O.;
Arat, M Ankara University Medical School Department of Hematology,
Ankara, Turkey.
Background: Allogeneic hematopoietic cell transplantation (Al-
loHCT); today, is still the only treatment modality that provides
cure for CML. But relapses after AlloHCT are still an ongoing
problem. In most of these patients donor lymphocyte infusions
(DLI) are effective to achieve molecular remission (MR). Post DLI
aplasia and GVHD are the most important reasons of morbidity
and mortality in these patients. Imatinib is a tyrosine kinase inhib-
itor and blocks CML progenitor cell proliferation. The effect of
imatinib on relapse after AlloHCT has been investigated in a few
studies including patients with chronic and accelerated phase
CML. In this study we aimed to analyze the effect of imatinib on
post AlloHCT molecular relapse. Patients and Method: Imatinib
was applied 400 mg/day p.o. at least for six months to 11 patients;
transplanted from their HLA identical siblings with molecular
relapse. Patients were monitored closely with ATM Multiplex
PCR for chimerism and RQ-PCR (LightCycler, Roche Diagnos-
tics) for bcr-abl/G6PDH. Results: Eleven of the patients were
under imatinib treatment for more than 6 months. Seven of the 11
patients responded to imatinib. At the end of the sixth month
except two patients all of them had donor type chimerism. Peri-
orbital edema developed in 4 of the patients, and none of the
patients had Gr 3–4 GIS and hematologic side effect. After cessa-
tion of the drug ﬁve patients had durable MR and complete
chimeric (CC) status. Two patients with second molecular relapse
and mix chimeric status after imatinib, and four patients with
primary imatinib resistance received DLI. After median 12 (6–20)
months follow up, imatinib sensitive 5 patients were in continuing
MR, imatinib sensitive two patients with second relapse were in
MR and CC after DLI. One of the imatinib refractory patients was
lost after DLI induced acute GVHD in MR, The remaining
patients did not achieve MR. One patient is still receiving DLI,
IFN and imatinib. Conclusion: Imatinib treatment for molecular
relapse after AlloHCT has acceptable adverse event proﬁle and
provides over 60% MR rate but this response was not durable as in
DLI; 25% of the patients experience second relapse early after
cessation of the drug. DLI may achieve MR in 50% of the primary
imatinib resistant patients. Concerning the in vitro effect if ima-
tinib on T cell functions there is an urgent need for prospective
studies comparing DLI and imatinib	DLI with close follow up of
chimerism.
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CAN WE CONSIDER FLUDARABINE/ FULL DOSE I.V. BUSULFAN A RE-
DUCED INTENSITY CONDITIONING REGIMEN?
Chunduri, S.; Jessop, E.; Dobogai, L.; Peace, D.; Saunthararajah, Y.;
Chen, Y.-H.; Mahmud, N.; Maynard, V.; Hoffman, R.; Rondelli, D.
University of Illinois at Chicago, Chicago, IL.
In this study we analyzed 22 patients who received an allogeneic
HSCT from matched related (n17) or unrelated (n5) donors,
and were conditioned with FLU/BU (ﬂudarabine 30 mg/m2/d  4
days followed by single dose i.v. busulfan 3.2 mg/kg/d  4 days)
(n12) or with the FLU/MEL (ﬂudarabine 30 mg/m2/d  5 days
and melphalan 70 mg/m2/d  2 days) (n10) RIC regimen. Me-
dian age was 26 yrs (range: 19–51) in the FLU/BU group and 47
yrs (range: 22–57) in the FLU/MEL group (p0.02). High risk
patients were 8/12 in the FLU/BU group (7 AML in relapse, 1
CML-AP) and 3/10 in the FLU/MEL group (2 resistant NHL and
1 HD). GVHD prophylaxis was FK-506/MTX and in 9/12
FLU/BU cases (including 5 MUD) Thymoglobulin was added. All
FLU/MEL and 6/12 FLU/BU patients received PBSC (median nr.
CD34 cells: 5.0 and 5.9 106/kg, respectively), while 6 FLU/BU
received marrow cells (median nr. CD34 cells: 1.58  106/kg).
Median time to ANC 500 was comparable in PBSC FLU/BU
(d14, range: 11–20), and PBSC FLU/MEL (d12, range: 10–15)
patients, while it was longer in bone marrow FLU/BU (d 22, range:
17–37) patients (p 0.01 and p0.001, respectively). Time to Plt
20K was d 12 (range: 10–16) in the PBSC FLU/MEL group and
d 20 (range: 17–37) in the bone marrow FLU/BUS group. Four of
6 PBSC FLU/BU patients did not have severe thrombocytopenia
(
20K) after transplant. Mucositis  grade 2 was never observed.
Median length of stay in the hospital after transplant was 17 days
(range: 13–37) in PBSC FLU/MEL, 23 days (range: 18–42) in
PBSC FLU/BU and 30 d (range: 22–38) in bone marrow FLU/
BU. Median chimerism levels on d30 after transplant were: 100%
in FLU/MEL and 95% (1 rejection) in FLU/BU. Median fol-
low-up for patients currently alive is 254 days (range: 145–628) in
the FLU/BU group and 636 days (range: 429–715) in the FLU/
MEL group. Acute GVHD grade II-IV was seen in 1 FLU/BU
patient after DLI and in 1 FLU/MEL patient. Chronic GVHD is
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